NEWS DESK

SLGL Stock News, News Score & What It Could Mean

Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently mixed earnings tone.

HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
OPEN ON TRADINGVIEW ↗TRADE THIS STOCK
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$77.22
Trend Context
Mixed / range
Latest briefing

What's happening with SLGL

globenewswire.com28 May 2026

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026 Sol-Gel signed an exclusiv…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Earnings news

SLGL earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
zacks.com28 May 2026

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.

2
globenewswire.com28 May 2026

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026 Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India NESS ZIONA, Israel, May

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your SLGL research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.
Stock AnalysisOPEN ON TRADINGVIEW ↗TRADE THIS STOCK